GlassScriptPhysician profile
Sarah M Canavan
NPI 1851488621
$4,250.53
in general payments reported to CMS, 2019-2025
30 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $168 · 2021: $298 · 2022: $40.78 · 2023: $726 · 2024: $803 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,481.46 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $379.18 | 2019-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $329.77 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $305.09 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.89 | 2019-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $272.07 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $239.31 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $97.13 | 2023-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $93.23 | 2019 | |
| Ironwood Pharmaceuticals, INC | $87.66 | 2019-2023 | Linzess |
| Ardelyx, INC. | $74.89 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $74.28 | 2024 | Sucraid |
| Pfizer INC. | $72.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $51.10 | 2024-2025 | Dupixent |
| Shire North American Group INC | $49.53 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $48.26 | 2024-2025 | |
| Allergan, INC. | $37.86 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $36.99 | 2023 | Kristalose |
| Amgen INC. | $26.45 | 2025 | |
| Fresenius Kabi USA, LLC | $25.27 | 2023 | Idacio |
| Pentax of America, INC. | $24.56 | 2025 | Pentax Medical, C2 Cryoballoon Focal Controller, Inspira |
| Aimmune Therapeutics, INC. | $23.68 | 2025 | Zenpep |
| Axonics, INC. | $23.59 | 2024 | Axonics |
| Evoke Pharma, INC. | $20.48 | 2025 | |
| Alfasigma USA, INC. | $18.40 | 2020 | |
| Intercept Pharmaceuticals, INC. | $16.29 | 2024 | |
| Braintree Laboratories, INC. | $15.00 | 2021 | |
| Biocon Biologics INC | $14.35 | 2025 | Yesintek |
| Amag Pharmaceuticals, INC. | $12.46 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Canavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.